6 August 2013
EMA/PDCO/435734/2013
Human Medicines Development and Evaluation

Paediatric Committee (PDCO)

Draft minutes of the 17-19 July 2013 meeting

Chair: Daniel Brasseur

I Introduction

I.1 Adoption of the minutes from previous meeting

Adopted.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.2 Adoption of the Agenda

Adopted.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.3 Declaration of Conflict of Interest

See Annex I.

I.4 External attendance

Please refer to the July 2013 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.5 Leaving/New Members and Alternates

Please refer to the July 2013 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

II Opinions

II.1 Opinions on Products

II.2 Opinions on Compliance Check

II.3 Opinions on Modification of an Agreed Paediatric Investigation Plan

Please refer to the July PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

III Discussion of applications

The PDCO discussed 86 procedures in total[1], of which:

- 37 paediatric investigation plan applications;
- 10 product-specific waiver applications;
- 3 compliance check procedures (interim and final);
- 36 requests for modifications of an agreed paediatric investigation plan.

IV Nomination of Rapporteurs and Peer reviewers

• List of letters of intent received for submission of applications with start of procedure September 2013[1]for Nomination of Rapporteur and Peer reviewer • Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver	The PDCO approved the lists of Rapporteurs and Peer Reviewers.

V Update and finalisation of opinions and requests for modification

All opinions taken at this meeting (relating to adoption of opinions, recommendations, requests for modifications and applicability of class waivers) were made in the presence of the required quorum of members.

The opinions adopted during the Paediatric Committee meeting of July 2013 are published in the same month's meeting report published in the EMA website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab.

[1] The procedures discussed by the PDCO are on-going and therefore are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

VI Discussion on the applicability of class waiver

Class waiver number	Active substance	Proposed indication	Condition	Outcome
EMEA-22-2013	(E)-4-[(5-Phenyl-1,3,4-thiadiazol-2-yl)oxy]-1-azoniatricyclo [3.3.1.13,7]decane 3,4-dicarboxy-3-hydroxybutanoate hydrate (PIP 1468)	Symptomatic treatment of mild to moderately severe Alzheimer's dementia	Treatment of Alzheimer's disease	Confirmed
EMEA-27-2013	RO5479599, RG7116, GE-huMab-HER3	Treatment of non-small cell lung carcinoma	Treatment of lung carcinoma (small cell and non-small cell)	Confirmed
EMEA-28-2013	RO5479599, RG7116, GE-huMab-HER3	Treatment of breast cancer	Treatment of breast carcinoma	Confirmed
EMEA-29-2013	Gantenerumab - RO4909832	• Disease modifying in prodromal (early) and mild stages of Alzheimer's disease • Disease modifying in individuals at risk for and with dominantly inherited Alzheimer's disease	Treatment of Alzheimer's Disease	Confirmed for the first proposed indication. However, the second indication was considered to address prevention of Alzheimer's disease and therefore not to be covered by the class waiver. A product-specific waiver should be submitted.
EMEA-30-2013	CC-223	Treatment of adult patients with unresectable hepatocellular carcinoma who have failed sorafenib	Treatment of liver and intrahepatic bile duct carcinoma (excluding hepatoblastoma)	Confirmed
EMEA-31-2013	CC-223	Treatment of adult patients with neuroendocrine tumour (NETs) of non-pancreatic origin	Treatment of gastroenteropancreatic neuroendocrine tumours (excluding neuroblastoma, neuroganglioblastoma, phaeochromocytoma)	Confirmed

EMEA-32-2013	BMN 673 [Poly (ADP-ribose) Polymerase (PARP) Inhibitor]	BMN 673 is intended as a monotherapy for treatment of patients with locally advanced or metastatic breast cancer with a BRCA 1 and/or BRCA 2 mutation	Treatment of breast carcinoma	Confirmed

VIII Annual reports on deferrals

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan drug	Difficulties progressing the PIP?	Outcome
EMEA-000117-PIP01-07	ipilimumab	Strentarga	No	Yes	The PDCO noted the reported delayed progress of the PIP compared to the planned initiation and completion dates and the modification procedure finalised at this meeting to address this.
EMEA-000117-PIP02-10	ipilimumab	YERVOY (subject to change during MAA procedure)	No	No	The PDCO noted the report.
EMEA-000335-PIP01-08-M07	ivacaftor	Kalydeco	No	No	The PDCO noted the report.
EMEA-000467-PIP01-08	Perampanel		No	No	The PDCO noted the report.
EMEA-001095-PIP02-12	Natalizumab	Tysabri	No	No	The PDCO noted the report.
EMEA-000015-PIP01-07	Doripenem monohydrate		No	Yes	The PDCO noted the temporarily halted

					paediatric trial and the planned modification request.
EMEA-000876-PIP01-10	eculizumab	SOLIRIS	Yes	No	The PDCO noted the reported delayed progress of the PIP compared to the planned completion date and the planned modification procedure to address this.
EMEA-000876-PIP02-11	Eculizumab	Soliris	Yes	No	The PDCO noted the report.
EMEA-000339-PIP02-09	Entecavir (monohydrate)	Baraclude	No	No	The PDCO noted the report.
EMEA-000548-PIP01-09	Beclometasone dipropionate plus formoterol fumarate dihydrate	FOSTER and associated names, KANTOS and associated names, KANTOS MASTER and associated names, INUVAIR and associated names	No	Yes	The PDCO noted the reported delayed progress of the PIP compared to the planned completion date and the planned modification procedure to address the issues raised.
EMEA-000520-PIP01-08	belimumab	BENLYSTA	No	No	The PDCO noted the report.
EMEA-000342-PIP01-08	Sunitinib malate	SUTENT	Yes	Yes	The PDCO noted the reported delayed progress of the PIP and

					the discussions in preceding modification procedures to address this.
EMEA-000019-PIP06-09	everolimus	Certican and associated names	No	Yes	The PDCO noted the reported delayed progress of the PIP compared to the planned completion date and the planned modification procedure to address this.

IX Other topics

Guidelines	
Revision of Pharmacovigilance guideline for paediatric medicines: rapporteur nomination	There is a need to revise the guideline on "conduct of Pharmacovigilance for medicines used by the paediatric population", adopted by CHMP in June 2006. There will be a joint collaboration between PDCO and PRAC for the revision of this guideline: 2 Rapporteurs will be appointed: a PDCO lead Rapporteur and a PRAC Rapporteur. Prior to revising the guideline, a concept paper should be drafted, adopted by both PDCO and PRAC and then released for a 3 month public consultation. The PDCO lead Rapporteur for the revision of this guideline was appointed and his nomination was endorsed by PDCO members.
Guideline on Pharmaceutical Development of Medicines for Paediatric Use	The guideline on Pharmaceutical Development of Medicines for Paediatric use will be published soon. An overview of the steps the guideline went through was given, followed by an explanation of its main principles and a presentation of its main content. PDCO members praised the drafting group for the work done and adopted the guideline.
Working groups	
Paediatric inventory	The inventory of paediatric needs for nephro-urology was finalised.
Paediatric oncology	The group did not meet.

Extrapolation	Extrapolation issues on a product specific PIP on spinal muscular atrophy were discussed. The Chair informed the group of his intention to stand down, a new chair was appointed. A rapporteur and co-rapporteur for drafting of the reflection paper were appointed.
Formulation	The Chair informed the PDCO of her intention to stand down as Chair in the near future. The PDCO chair and members congratulated her on the work done.
Non-Clinical	No non-product related issues where reported to the Committee.
Other topics	
5-year report on the Paediatric regulation, Paediatric-use marketing authorisations (PUMAs)	The European Commission was represented at the meeting by their legal advisor assigned to the implementation of the Paediatric Regulation, who presented the EC 5-year report on the Paediatric regulation that was provided to the European Parliament this year. Additionally, the PDCO was informed that the Director-General of the Health and Consumers Directorate has written a letter to the Executive Director of the Agency, thanking the Agency, its PDCO and specifically the Paediatric Medicines team for, among other things, "all the hard work that was put into the implementation of the Regulation, in order to make the instrument a success". The letter also specifies that a PIP intended for a future PUMA application does not have to cover necessarily all paediatric subsets, and this has been included in the EC 5-year report on the Paediatric regulation (5.2, page 11).
Update on Enpr-EMA activities	The committee was informed about the outcomes of the 5th Enpr-EMA open workshop on 27th June. Several ad hoc Working Groups were set up to develop pragmatic responses to the needs (see below) that can be implemented within six months. - Approaches to priority setting - How to establish communication between Enpr-EMA, networks and industry - Dialogue and interaction with Ethics Committees - Sharing good practices within EnprEMA and with industry - Framework for networks to interact with industry and regulators when conduct of clinical trials no longer possible There is already good practice in many of these areas; EnprEMA needs to focus on disseminating good practice rather than developing new solutions. PDCO members are invited to express their interest for actively participating in one or more of the working groups.

Standard PIP for Gaucher disease*	The PDCO were informed that after considerable delay, the proposal for a multi-product, multi-company study (which had been review by SAWP) was now finally moving forward again as a Standard PIP. The current proposal had been presented at the July FDA TC, and would be discussed again at the August FDA TC for finalisation. PDCO were asked to comment in writing by 1 August, for adoption at the August PDCO.
Paediatric needs for nephro-urology *	The PDCO adopted the inventory of paediatric needs for the therapeutic area of nephro-urology for public consultation.
Priority list for off-patent medicines for children	The PDCO adopted the revised list.
Workshop for the treatment of multiple sclerosis	The PDCO was informed that registration is open for this workshop taking place at the EMA on 17 October 2013.
Standard PIP for Influenza pandemic vaccine	A revision of the standard PIP for pandemic influenza vaccine was presented for comments to the PDCO before discussion at VWP.

Any other business

Note on access to documents

Documents marked with an asterisk* in these minutes cannot be released at present as they are currently in draft format. They will become public when adopted in their final form.

Annex I to the Minutes of the PDCO of July 2013

Documentation on Declaration of interest of members, alternates and experts

Based on the Declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of Committee members for the upcoming discussions.

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests).

Based on the Declaration of Interest submitted by the Committee members, alternates and experts, the Committee Secretariat identified, based on the topics listed in the Agenda of the current Committee meeting, the following restricted involvement of Committee members for the upcoming discussions:

Member, alternate, expert name	Outcome restriction following evaluation of electronic evaluation form	Topics on the current Committee Agenda for which this restriction applies
Jean-Pierre Aboulker	XR	EMEA-001457-PIP01-13
Jean-Pierre Aboulker	XR	EMEA-000117-PIP01-07-M05
Jean-Pierre Aboulker	XR	EMEA-000689-PIP01-09-M04
Jean-Pierre Aboulker	XR	EMEA-001469-PIP01-13
Jean-Pierre Aboulker	XR	EMEA-001465-PIP01-13
Jean-Pierre Aboulker	XR	EMEA-000019-PIP09-13
Adriana Ceci	Level 3	EMEA-001315-PIP01-12
Adriana Ceci	XR	EMEA-000019-PIP09-13
Adriana Ceci	XR	EMEA-000880-PIP02-11-M02
Alexandra Compagnucci	XR	EMEA-001457-PIP01-13
Alexandra Compagnucci	XR	EMEA-000689-PIP01-09-M04
Alexandra Compagnucci	XR	EMEA-001469-PIP01-13
Alexandra Compagnucci	XR	EMEA-001465-PIP01-13
Alexandra Compagnucci	XR	EMEA-000019-PIP09-13
Alexandra Compagnucci	XR	EMEA-000117-PIP01-07-M05
Carine de Beaufort	XR	EMEA-001469-PIP01-13
Carine de Beaufort	XR	EMEA-000731-PIP01-09-M01

Member, alternate, expert name	Outcome restriction following evaluation of electronic evaluation form	Topics on the current Committee Agenda for which this restriction applies
Kolbeinn Gudmundsson	DP	EMEA-001348-PIP01-12
Dobrin Konstantinov	DP	EMEA-000019-PIP09-13
Christoph Male	XP	EMEA-001114-PIP01-10-M01
Christoph Male	XP	EMEA-000914-PIP01-10-M01
Christoph Male	Level 3	EMEA-000778-PIP02-12
Christoph Male	XP	EMEA-001456-PIP01-13
Michal Odermarsky	XP	EMEA-000317-PIP01-08-M04
Michal Odermarsky	XP	EMEA-001465-PIP01-13
Michal Odermarsky	XP	EMEA-001460-PIP01-13
Michal Odermarsky	XP	EMEA-001442-PIP01-13
Paolo Rossi	DP	EMEA-000872-PIP02-13
Paolo Rossi	XR	EMEA-001469-PIP01-13
Paolo Rossi	XR	EMEA-001458-PIP01-13
Paolo Rossi	XR	EMEA-001429-PIP01-13
Paolo Rossi	XR	EMEA-001442-PIP01-13
Paolo Rossi	XR	EMEA-000731-PIP01-09-M01
Jaroslav Sterba	XP	EMEA-001429-PIP01-13
Jarolsav Sterba	XP	EMEA-000019-PIP09-13

Note: the procedures identified in the table above are on-going and therefore considered commercially confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

No new or additional conflicts were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.

Restriction levels:

Evaluation of the conflict of interest	
Outcome	Impact
R-P	To be replaced for the discussions, final deliberations and voting as appropriate in relation to the relevant product or a competitor product.

XP	Where Individual product involvement is declared - PRODUCT INDICATION: - No involvement with respect to procedures involving the relevant product or a competitor product in the relevant indication i.e. no part in discussions, final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products - [Cannot act as Rapporteur for development of guidelines in concerned therapeutic area].
XC	Where cross product / general involvement is declared - COMPANY: - No involvement (as outlined above) with respect to products from the specified company. - Cannot act as Rapporteur for products from the relevant company(ies).
DP	Where Individual product involvement is declared - PRODUCT INDICATION: - Involvement in discussions only with respect to procedures involving the relevant product or a competitor product i.e. no part in final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products.
DC	Where cross product / general involvement is declared - COMPANY: - Involvement in discussions only with respect to products from the specified company. - Cannot act as Rapporteur on products from the relevant company(ies).
XR	Committee member cannot act as Rapporteur or Peer reviewer in relation to any medicinal product from the relevant company.
R-C	To be replaced for the discussions, final deliberations and voting as appropriate in relation to any medicinal product from the relevant company

Evaluation of the conflict of interest – Previous code	
Outcome	Impact
1	No involvement in activity
2	To be replaced for the discussions, final deliberations and voting as appropriate in relation to the relevant product or a competitor product.
3	Where Individual product involvement is declared: - No involvement with respect to procedures involving the relevant product or a competitor product in the relevant indication, i.e. no part in discussions, final deliberations and voting as appropriate as regards these medicinal products.
4	Where Individual product involvement is declared: - Involvement in discussions only with respect to procedures involving the relevant product or a competitor product, i.e. no part in final deliberations and voting as appropriate as regards these medicinal product.

Annex II to the Minutes of the PDCO of July 2013

List of Participants

Chair

Daniel BRASSEUR

Vice-chair

Dirk MENTZER

Members appointed by Member States or CHMP

Karl Heinz HUEMER	Austria
Marina DIMOV DI GUSTI	Croatia
George SAVVA	Cyprus
Marianne ORHOLM	Denmark
Irja LUTSAR	Estonia
Pirjo LAITINEN-PARKONNEN	Finland
Sylvie BENCHETRIT	France
Dirk MENTZER	Germany
Agnes GYURASICS	Hungary
Kevin CONNOLLY	Ireland
Dina APELE-FREMIANE	Latvia
Carine de BEAUFORT	Luxembourg
Hendrik van den BERG	The Netherlands
Siri WANG	Norway
Helena FONSECA	Portugal
Fernando DE ANDRÉS TRELLES	Spain
Viveca Lena ODLIND	Sweden
Julia DUNNE	United Kingdom

Alternates appointed by Member States or CHMP

Jacqueline CARLEER	Belgium
Bernard KAIC	Croatia
Peter SZITANYI	Czech Republic

Marta GRANSTRÖM	Denmark
Jana LASS	Estonia
Ann Marie KAUKONEN	Finland
Birka LEHMANN	Germany
Herbert LENICKER	Malta
Jolanta WITKOWSKA-OZOGOWSKA	Poland
Dana Gabriela MARIN	Romania
Maria Jesus FERNANDEZ CORTIZO	Spain
Ninna GULLBERG	Sweden
Angeliki SIAPKARA	United Kingdom

Members representing patients' organisations

Tsveta SCHYNS-LIHARSKA

Members representing health care professionals

Adriana CECI

Anthony James NUNN

Alternates representing health care professionals

Paolo PAOLUCCI

Experts

Peter BAUER	Medical statistician
Eleni GAKI	Medicines and Healthcare products Regulatory Agency
Martina RIEGL	Medicines and Healthcare products Regulatory Agency

Observers

Maaike van DARTEL	College ter Beoordeling van Geneesmiddelen

European Medicines Agency

Agnes SAINT RAYMOND	Head of Sector, Human Medicines Special Areas
Paolo TOMASI	Head of Section, Paediatric Medicines
Sophie OLIVIER	Scientific Administrator, Paediatric Medicines
Anne-Sophie HENRY-EUDE	Scientific Administrator, Paediatric Medicines
Benjamin PELLE	Scientific Administrator, Paediatric Medicines
Chrissi Pallidis	Scientific Administrator, Paediatric Medicines
Dobromir PENKOV	Scientific Administrator, Paediatric Medicines

Elin Haf DAVIES	Scientific Administrator, Paediatric Medicines
Giovanni LESA	Scientific Administrator, Paediatric Medicines
Gunter EGGER	Scientific Administrator, Paediatric Medicines
Irmgard EICHLER	Scientific Administrator, Paediatric Medicines
Janina KARRES	Scientific Administrator, Paediatric Medicines
Peter KÁROLYI	Scientific Administrator, Paediatric Medicines
Ralf HEROLD	Scientific Administrator, Paediatric Medicines
Ralph BAX	Scientific Administrator, Paediatric Medicines
Richard VESELY	Scientific Administrator, Paediatric Medicines
Thorsten OLSKI	Scientific Administrator, Paediatric Medicines
Alessandro JENKNER	National Expert on Secondment, Paediatric Medicines
Aneta KRZYSCIAK	Assistant, Paediatric Medicines
Aurelie HERVIEU	Assistant, Paediatric Medicines